Clinical and Magnetic Resonance Imaging Outcomes of Microfracture Plus Chitosan/Blood Implant vs Microfracture for Osteochondral Lesions of the Talus

ArticleAçık Erişim

Özet

Background: The aim of this study was to compare the clinical and magnetic resonance imaging (MRI) outcomes of arthroscopic microfracture (MF) plus chitosan-glycerol phosphate/blood implant and MF alone for the treatment of the osteochondral lesions of the talus (OCLTs). Methods: Patients who underwent either MF plus chitosan (group 1, n = 32) or MF alone (group 2, n = 31) between 2015 and 2019 in 2 separate time periods were retrospectively analyzed. Visual analog scale (VAS) score and American Orthopaedic Foot & Ankle Society (AOFAS) score were used for clinical evaluation. The magnetic resonance observation of cartilage repair tissue (MOCART) system was used for MRI evaluation. The mean follow-up time was 32 ± 13 months (range, 12-61 months). Results: Postoperatively, we detected significant improvements in both groups in terms of VAS and AOFAS scores. However, we observed no statistically significant difference between groups in terms of clinical scores, except the mean VAS function score, which was significantly higher in group 1 (P =.022). According to MOCART scale, complete repair with the filling of the chondral defect and intactness of the surface of the repair tissue were more common in group 1. However, these parameters did not significantly differ between groups (P =.257 and.242, respectively). Conclusion: Arthroscopic MF plus chitosan glycerol phosphate/blood implant did not result in better clinical and MRI outcomes compared with MF alone in the treatment of OCLTs. Level of Evidence: Level III, retrospective comparative study. © The Author(s) 2020.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13069Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1177/1071100720942173Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCamurcu, Yalkin
dc.contributor.authorUcpunar, Hanifi
dc.contributor.authorYapici, Furkan
dc.contributor.authorKarakose, Resit
dc.contributor.authorOzcan, Seckin
dc.contributor.authorCobden, Adem
dc.contributor.authorDuman, Serda
dc.contributor.authorSofu, Hakan
dc.date.accessioned2026-10-18T20:27:54.742412502Z
dc.date.available2026-10-18T20:27:54.742412502Z
dc.date.issued2020
dc.description.abstractBackground: The aim of this study was to compare the clinical and magnetic resonance imaging (MRI) outcomes of arthroscopic microfracture (MF) plus chitosan-glycerol phosphate/blood implant and MF alone for the treatment of the osteochondral lesions of the talus (OCLTs). Methods: Patients who underwent either MF plus chitosan (group 1, n = 32) or MF alone (group 2, n = 31) between 2015 and 2019 in 2 separate time periods were retrospectively analyzed. Visual analog scale (VAS) score and American Orthopaedic Foot & Ankle Society (AOFAS) score were used for clinical evaluation. The magnetic resonance observation of cartilage repair tissue (MOCART) system was used for MRI evaluation. The mean follow-up time was 32 ± 13 months (range, 12-61 months). Results: Postoperatively, we detected significant improvements in both groups in terms of VAS and AOFAS scores. However, we observed no statistically significant difference between groups in terms of clinical scores, except the mean VAS function score, which was significantly higher in group 1 (P =.022). According to MOCART scale, complete repair with the filling of the chondral defect and intactness of the surface of the repair tissue were more common in group 1. However, these parameters did not significantly differ between groups (P =.257 and.242, respectively). Conclusion: Arthroscopic MF plus chitosan glycerol phosphate/blood implant did not result in better clinical and MRI outcomes compared with MF alone in the treatment of OCLTs. Level of Evidence: Level III, retrospective comparative study. © The Author(s) 2020.
dc.identifier.doi10.1177/1071100720942173
dc.identifier.eissn1944-7876
dc.identifier.endpage1375
dc.identifier.issn1071-1007
dc.identifier.issue11
dc.identifier.pmid32757833
dc.identifier.scopus2-s2.0-85089189612
dc.identifier.startpage1368
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13069
dc.identifier.volume41
dc.identifier.wosWOS:000556857000001
dc.language.isoen
dc.publisherSAGE Publications Inc.
dc.relation.ispartofFoot and Ankle International
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectarthroscopy
dc.subjectblood implant
dc.subjectchitosan-glycerol phosphate
dc.subjectmicrofracture
dc.subjectosteochondral lesion
dc.subjecttalus
dc.subjectAdult
dc.subjectBiocompatible Materials
dc.subjectBlood
dc.subjectBone Diseases
dc.subjectCartilage Diseases
dc.subjectChitosan
dc.subjectFemale
dc.subjectFractures, Stress
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPain Measurement
dc.subjectRetrospective Studies
dc.subjectSurveys and Questionnaires
dc.subjectcephalosporin
dc.subjectglycerophosphate
dc.subjectnonsteroid antiinflammatory agent
dc.subjectbiomaterial
dc.subjectAmerican Orthopedic Foot and Ankle Society score
dc.subjectankle hematoma
dc.subjectArticle
dc.subjectassessment of humans
dc.subjectbody mass
dc.titleClinical and Magnetic Resonance Imaging Outcomes of Microfracture Plus Chitosan/Blood Implant vs Microfracture for Osteochondral Lesions of the Talus
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus10
rdl.citation.wos7
rdl.departmentDepartment of Orthopaedics and Traumatology, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)